Clinical Trial

A Trial of Recaticimab and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable BTC

Name: A Trial of Recaticimab and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable BTC — clinical trial record (NCT07062328)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: HP-BTC-002

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The study aims to evaluate the efficacy and safety of Recaticimab and Adebrelimab in Combination With chemotherapy in patients with metastatic biliary tract carcinoma (BTC).

Trial Details

NCT Number	NCT07062328
Lead Sponsor	Sun Yat-sen University Collaborators: Jiangsu Hengrui Pharmaceutical Co., Ltd.
Conditions	Biliary Tract Carcinoma
Enrollment	39 participants
Start Date	2025-07-10
Primary Completion	2026-12-10 (estimated)
Study Completion	2028-04-20 (estimated)
Updated on ClinicalTrials.gov	2025-07-14